Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy

WAF1, a potential mediator of p53 tumor suppression

El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321

p53 Mutations in Human Cancers

Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018

p53, the cellular gatekeeper for growth and division

Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693

Surfing the p53 network

Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661

p21 is a universal inhibitor of cyclin kinases

Xiong, Y., Hannon, G., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,691

Live or let die: the cell's response to p53

Vousden, K. H., & Lü, X. (2002) · Nature reviews. Cancer · doi:10.1038/nrc864 · Cited by 3,231

The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation

Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113

Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage

Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803

The p53 pathway: positive and negative feedback loops

Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967

MDM2 in Tumor Biology and Cancer Therapy: A Review of Current Clinical Trials

Russano, F., Sturlese, M., Dall’Olmo, L., Callegarin, F., Brugnolo, D., Fiore, P. D., Patti, V., Purpura, A. H.-S., Moro, S., Rastrelli, M., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010099 · Cited by 14

Molecular evidence of Zn chelation of the procaspase activating compound B-PAC-1 in B cell lymphoma

Sarkar, A. K., Balakrishnan, K., Chen, J. W., Patel, V. M., Neelapu, S. S., McMurray, J. S., & Gandhi, V. V. (2015) · Oncotarget · doi:10.18632/oncotarget.6505 · Cited by 10

Induction of apoptosis in Ehrlich ascites tumour cells via p53 activation by a novel small-molecule MDM2 inhibitor – LQFM030

da Mota, M. F., Cortez, A. P., Benfica, P. L., Rodrigues, B. D. S., Castro, T. F., Macedo, L. M., Castro, C. H., Lião, L. M., de Carvalho, F. S., Romeiro, L. A. S., et al. (2016) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12573 · Cited by 10

Progress in the research of p53 tumour suppressor activity controlled by Numb in triple‐negative breast cancer

Xian, J., Cheng, Y., Qin, X. Y., Luo, Y., Cao, Y., & Cao, Y. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15366 · Cited by 9

P-TEFb promotes cell survival upon p53 activation by suppressing intrinsic apoptosis pathway

Wang, Z., Mačáková, M., Bugai, A., Kuznetsov, S. G., Hassinen, A., Lenasi, T., Potdar, S., Friedel, C. C., & Barborič, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad001 · Cited by 11

Bridged Analogues for p53-Dependent Cancer Therapy Obtained by S-Alkylation

Micewicz, E. D., Sharma, S. K., Waring, A. J., Luong, H. T., McBride, W. H., & Ruchala, P. P. (2015) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-015-9487-3 · Cited by 11

Taraxasterol regulates p53 transcriptional activity to inhibit pancreatic cancer by inducing MDM2 ubiquitination degradation

Han, A., Liu, J., Du, P., Li, W., Quan, H., Lin, Z., & Chen, L. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156298 · Cited by 9

Identification of a small-molecule RPL11 mimetic that inhibits tumor growth by targeting MDM2-p53 pathway

Wang, B., Gao, J., Zhao, Z., Zhong, X., Cui, H., Hou, H., Zhang, Y., Zheng, J., Di, J., & Liu, Y. (2022) · Molecular Medicine · doi:10.1186/s10020-022-00537-x · Cited by 9

A Novel MDM2-Binding Chalcone Induces Apoptosis of Oral Squamous Cell Carcinoma

Wermelinger, G. F., Rubini-Dias, L., da Fonseca, A. C. C., Ouverney, G., de Oliveira, R. P. R. F., de Souza, A. S., Forezi, L. D. S. M., Limaverde‐Sousa, G., Pinheiro, S., & Robbs, B. K. (2023) · Biomedicines · doi:10.3390/biomedicines11061711 · Cited by 9

Modeling the Etiology of p53-mutated Cancer Cells

Perez, R. E., Shen, H., Duan, L., Kim, R. H., Kim, T., Park, N.-H., & Maki, C. G. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.724781 · Cited by 9

Tetra-substituted pyrrole derivatives act as potent activators of p53 in melanoma cells

Proto, M., Fiore, D., Forte, G., Cuozzo, P., Ramunno, A., Fattorusso, C., Gazzerro, P., Pascale, M. C., & Franceschelli, S. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00813-4 · Cited by 9

p53: Balancing tumour suppression and implications for the clinic

Buganim, Y., & Rotter, V. (2009) · European Journal of Cancer · doi:10.1016/s0959-8049(09)70037-1 · Cited by 9

Molecular pathology and potential therapeutic targets in soft-tissue sarcoma

Todd, R., & Lunec, J. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.6.939 · Cited by 9

Loss of heterozygosity of the p53 gene and deregulated expression of its mRNA and protein in human brain tumors

Rohini, K., Jothi, M., Prabhu, P. D. A. H., Subbakrishna, D., Gope, M. L., Chandramouli, B. A., Sampath, S., Anandh, B., & Gope, R. (2006) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-006-9374-5 · Cited by 9

Protein-Protein Interactions as Drug Targets

Wendt, M. D. (2012) · Topics in Medicinal Chemistry · doi:10.1007/978-3-642-28965-1_1 · Cited by 9

QSAR Models for isoindolinone‐based p53–MDM2 Interaction Inhibitors Using Linear and Non‐linear Statistical Methods

Dong, X., Yan, J., Dong, L., Wu, P., Gao, J., Liu, T., Yang, B., & Hu, Y. (2012) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2012.01322.x · Cited by 8

TranSNPs: A class of functional SNPs affecting mRNA translation potential revealed by fraction-based allelic imbalance

Valentini, S., Marchioretti, C., Bisio, A., Rossi, A., Zaccara, S., Romanel, A., & Inga, A. (2021) · iScience · doi:10.1016/j.isci.2021.103531 · Cited by 8

Development of MDM2‐Targeting PROTAC for Advancing Bone Regeneration

Jeong, S., Cha, J., Ahmed, W., Kim, J., Kim, M., Hong, K. T., Choi, W., Choi, S., Yoo, T. H., An, H., et al. (2025) · Advanced Science · doi:10.1002/advs.202415626 · Cited by 9

A cleavage-based surrogate reporter for the evaluation of CRISPR–Cas9 cleavage efficiency

Jung, S. B., Lee, C. Y., Lee, K., Heo, K., & Choi, S. H. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab467 · Cited by 8

Nutlin-1 strengthened anti-proliferation and differentiation-inducing activity of ATRA in ATRA-treated p-glycoprotein deregulated human myelocytic leukemia cells

Zhang, L., Yan, Y., Zhu, D., Yang, W., Wang, W., Hu, Y., Yang, B., & He, Q. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9512-5 · Cited by 8

New developments in small molecules targeting p53 pathways in anticancer therapy

Cheok, C. F., & Lane, D. P. (2008) · Drug Development Research · doi:10.1002/ddr.20261 · Cited by 8

Discovery of novel candidates for anti-liposarcoma therapies by medium-scale high-throughput drug screening

Grad, I., Hanes, R., Durán, P. A., Kuijjer, M. L., Enserink, J. M., Meza‐Zepeda, L. A., & Myklebost, O. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248140 · Cited by 8

Heterogeneity of Phase II Enzyme Ligands on Controlling the Progression of Human Gastric Cancer Organoids as Stem Cell Therapy Model

Wu, D., Ku, C., Pan, J.-B., Wuputra, K., Yang, Y.-H., Liu, C., Liu, Y., Kato, K., Saito, S., Lin, Y., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115911 · Cited by 8

p53 in the mitochondria, as a trans-acting protein, provides error-correction activities during the incorporation of non-canonical dUTP into DNA

Bonda, E., Rahav, G., Kaya, A., & Bakhanashvili, M. (2016) · Oncotarget · doi:10.18632/oncotarget.12331 · Cited by 8

Mouse Double Minute 2 Actively Suppresses p53 Activity in Oocytes during Mouse Folliculogenesis

Zhang, C.-X., Zhang, Q., Xie, Y., He, X., Xiang, C., Hou, X., Zhou, Y., Chen, L., Zhang, G.-X., & Liu, G. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.09.023 · Cited by 8

Determination of nutlin-3a in murine plasma by liquid chromatography electrospray ionization tandem mass spectrometry (LC–ESI-MS/MS)

Bai, F., Zhu, F., Tagen, M., Miller, L. A., Owens, T. S., Mallari, J. P., Derrick, E., Zhang, F., & Stewart, C. F. (2009) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2009.10.016 · Cited by 8

Integrated stress response (ISR) activation and apoptosis through HRI kinase by PG3 and other p53 pathway-restoring cancer therapeutics

Tian, X., & El‐Deiry, W. S. (2024) · Oncotarget · doi:10.18632/oncotarget.28637 · Cited by 8

Dual functionality of MDM2 in PROTACs expands the horizons of targeted protein degradation

Zhao, J., Chen, H., & Liang, C. (2025) · Biomarker Research · doi:10.1186/s40364-025-00826-7 · Cited by 7

Combination therapy with p53–MDM2 binding inhibitors for malignancies

Jin, Z., Shen, J., He, J.-Y., & Hu, C. (2014) · Medicinal Chemistry Research · doi:10.1007/s00044-014-1089-7 · Cited by 7

Direct Catalytic Enantioselective Reaction of α-Isocyanoacetonitriles with Ketimines Using Cinchona Alkaloid Amide–Cu(II) Catalysts

Nakamura, S., Kibe, M., Takehara, T., & Suzuki, T. (2023) · Organic Letters · doi:10.1021/acs.orglett.3c00259 · Cited by 7

Calix[4]arene–pyrazole conjugates as potential cancer therapeutics

Muravev, A. A., Voloshina, A. D., Sapunova, A. S., Gabdrakhmanova, F. B., Lenina, O. A., Petrov, K. A., Shityakov, S., Скорб, Е. В., Solovieva, S. Е., & Antipin, I. S. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106742 · Cited by 7

Regulatory network of differentially expressed genes in metastatic osteosarcoma

YAO, P., WANG, Z.-B., DING, Y.-Y., MA, J.-M., Hong, T., Pan, S., & Zhang, J. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.3009 · Cited by 7

Proteasome modulators: essential chemical genetic tools for understanding human diseases

Wehenkel, M., Hong, J. T., & Kim, K. B. (2008) · Molecular BioSystems · doi:10.1039/b716221a · Cited by 7

TRIAD1 Is a Novel Transcriptional Target of p53 and Regulates Nutlin‐3a‐Induced Cell Death

Lee, J., An, S., Choi, Y. M., Jung, J. H., Li, L., Meng, H., Dong, Y., Ahn, K. J., An, I., & Bae, S. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25831 · Cited by 7

Topological integration of RPPA proteomic data with multi-omics data for survival prediction in breast cancer via pathway activity inference

Kim, T. R., Jeong, H.-H., & Sohn, K.-A. (2019) · BMC Medical Genomics · doi:10.1186/s12920-019-0511-x · Cited by 7

Induced Pluripotent Stem Cells to Model Juvenile Myelomonocytic Leukemia: New Perspectives for Preclinical Research

Wehbe, Z., Ghanjati, F., & Flotho, C. (2021) · Cells · doi:10.3390/cells10092335 · Cited by 8

A Cyclized Helix‐Loop‐Helix Peptide as a Molecular Scaffold for the Design of Inhibitors of Intracellular Protein–Protein Interactions by Epitope and Arginine Grafting

Fujiwara, D., Kitada, H., Oguri, M., Nishihara, T., Michigami, M., Shiraishi, K., Yuba, E., Nakase, I., Im, H., Cho, S., et al. (2016) · Angewandte Chemie · doi:10.1002/ange.201603230 · Cited by 7

Fortifying p53 – beyond Mdm2 inhibitors

Sriraman, A., Li, Y., & Dobbelstein, M. (2016) · Aging · doi:10.18632/aging.101073 · Cited by 6

Unmet Horizons: Assessing the Challenges in the Treatment of TP53-Mutated Acute Myeloid Leukemia

Stafylidis, C., Vlachopoulou, D., Kontandreopoulou, C., & Diamantopoulos, P. T. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13041082 · Cited by 6

Synthesis and biological evaluation of 4-imidazolidinone–containing compounds as potent inhibitors of the MDM2/p53 interaction

Lin, Z., Liu, C., Yan, Z., Cheng, J., Wang, X., Zhou, F., Lyu, X., Zhang, S., Zhang, D., Meng, X., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116366 · Cited by 7

FAM193A is a positive regulator of p53 activity

Szwarc, M. M., Guarnieri, A. L., Joshi, M., Duc, H. N., Laird, M. C., Pandey, A., Khanal, S., Dohm, E., Bui, A. K., Sullivan, K. D., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112230 · Cited by 6

Wilms’ tumor gene 1 enhances nutlin-3-induced apoptosis

Lee, S.-Y., Choe, Y.-J., Park, J. Y., Lee, S. S., Kim, Y.-H., Shin, S. J., Chung, Y. J., & Kim, H. (2013) · Oncology Reports · doi:10.3892/or.2013.2832 · Cited by 6

Homozygousmdm2SNP309 cancer cells with compromised transcriptional elongation at p53 target genes are sensitive to induction of p53-independent cell death

Rosso, M., Polotskaia, A., & Bargonetti, J. (2015) · Oncotarget · doi:10.18632/oncotarget.5312 · Cited by 6

Nutlin-3 inhibits androgen receptor-driven c-FLIP expression, resulting in apoptosis of prostate cancer cells

Logan, I. R., McClurg, U. L., Jones, D. L., O’Neill, D. J., Shaheen, F. S., Lunec, J., Gaughan, L., & Robson, C. N. (2016) · Oncotarget · doi:10.18632/oncotarget.12542 · Cited by 6

Comparison of the antitumor effects of an MDM2 inhibitor, nutlin-3, in feline lymphoma cell lines with or without p53 mutation

Mochizuki, H., Goto‐Koshino, Y., Sato, M., Fujino, Y., Ohno, K., & Tsujimoto, H. (2012) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2012.04.017 · Cited by 6

Targeting mutant p53 in cancer: from mechanistic insights to therapeutic strategies

Wu, H. H., Leng, S., Eisenstat, D. D., Sergi, C. M., & Leng, R. P. (2026) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-026-00907-x · Cited by 6

Effective and Practical Stereoselective Synthesis of Nutlins Precursors by Immobilization of Privileged Chiral Mono‐Amidine Catalyst

Toldo, S., Poletti, L., Carmine, G. D., Bortolini, O., Risi, C. D., Felletti, S., Compagnin, G., Massi, A., & Ragno, D. (2025) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.202500058 · Cited by 5

Global dynamics and stability of p53-Mdm2 oscillator mediated by Mdm2 production rate

Yuan-hong, B., Yang, Z., & Xiao-Yan, H. (2016) · Acta Physica Sinica · doi:10.7498/aps.65.028701 · Cited by 5

Rational Design Strategies for Developing Synthetic Inhibitors of Helical Protein Interfaces

Mahon, A. B., Miller, S. E., Joy, S. T., & Arora, P. S. (2012) · Topics in medicinal chemistry · doi:10.1007/978-3-642-28965-1_6 · Cited by 5

The Clinical and Therapeutic Uses of MDM2 and PSMA and Their Potential Interaction in Aggressive Cancers

Bradbury, R., Jiang, W. G., & Cui, Y. (2015) · Biomarkers in Medicine · doi:10.2217/bmm.15.94 · Cited by 5

Recent advances in mutant p53 and novel personalized strategies for cancer therapy

Lu, S.-Q., Jia, S., & Luo, Y. (2011) · Hereditas (Beijing) · doi:10.3724/sp.j.1005.2011.00539 · Cited by 5

SHORT REPORT Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A

Paulsen, E. B., Noordhuis, P., Pédeutour, F., Sæter, G., & Myklebost, O. (2007) · Cited by 5

Discovery of SCY45, a Natural Small‐Molecule MDM2‐p53 Interaction Inhibitor

Gong, H., An, J., Dong, Q., Li, J., Yang, W., Sun, W., Su, Z., & Zhang, S. (2019) · Chemistry & Biodiversity · doi:10.1002/cbdv.201900081 · Cited by 5

High-content morphological profiling by Cell Painting in 3D spheroidsPreprint

Ringers, C., Holmberg, D., Flobak, Å., Georgieva, P., Jarvius, M., Johansson, M. M., Larsson, A. O., Rosén, D., Seashore-Ludlow, B. A., Visnes, T., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.05.636642 · Cited by 5

MDM2 Antagonist Nutlin-3 Stimulates Global DNA Hydroxymethylation by Enhancing p53–TET1 Signaling Axis

Wu, D., Li, Y., Li, C., Zhong, S., Liu, B., Hang, H., & Wang, H. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.3c00247 · Cited by 3

Targeting anti-apoptotic mechanisms in tumour cells: Strategies for enhancing Cancer therapy

Chaudhary, B., Arya, P., Sharma, V., Kumar, P., Singla, D., & Grewal, A. S. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108388 · Cited by 5

Protein/ Hormone Based Nanoparticles as Carriers for Drugs Targeting Protein-Protein Interactions

Al-Suhaimi, E. A., Ravinayagam, V., Jermy, B. R., Tarhini, M., & Elaı̈ssari, A. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190304152320 · Cited by 4

Cell Death and Cancer

Vaux, D. L. (2013) · Springer eBooks · doi:10.1007/978-1-4614-9302-0_6 · Cited by 4

Small Molecules As pro-apoptotic Anticancer Agents

Seneci, P. (2012) · Pharmaceutical Patent Analyst · doi:10.4155/ppa.12.41 · Cited by 4

Selecting the Right Targets for Cancer Therapy

Bronchud, M. H. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-470-4_1 · Cited by 4

Model-based optimization of combination protocols for irradiation-insensitive cancers

Hat, B., Jaruszewicz-Błońska, J., & Tomasz Lipniacki, B. (2020) · Scientific Reports · doi:10.1038/s41598-020-69380-6 · Cited by 4

XPC Deficiency Activate Cisplatin‐Mediated Autophagy in Bladder Cancer by Limiting Novel PHRF1‐Mediated Ubiquitination of the p53 Protein

Zhao, B., Huang, Y., Shi, J., Zhou, X., Fagman, J. B., Wang, L., Liu, S., Wang, W., Liu, Y., Chen, Z., et al. (2025) · Advanced Science · doi:10.1002/advs.202517563 · Cited by 3

Targeting MDM2, RAS, and PCNA for cancer targeted therapy: pan-cancer approaches vs. cancer-specific strategies

Wang, W., Alley, A., Sun, N., Tadesse, M., Wang, X., & Zhang, R. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1663766 · Cited by 3

Targeting the MDM2–p53 interaction as a therapeutic strategy for the treatment of cancer

Peirce, S. K. (2010) · Cell Health and Cytoskeleton · doi:10.2147/chc.s4952 · Cited by 3

A Quantitative Systems Approach to Define Novel Effects of Tumour p53 Mutations on Binding Oncoprotein MDM2

Fuentes, M., Srivastava, S., Gronenborn, A. M., & LaBaer, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010053 · Cited by 3

Bioorthogonal Probes for the Study of MDM2‐p53 Inhibitors in Cells and Development of High‐Content Screening Assays for Drug Discovery

D’Alessandro, P. L., Buschmann, N., Kaufmann, M., Furet, P., Baysang, F., Brunner, R., Marzinzik, A. L., Vorherr, T. E., Stachyra, T., Ottl, J., et al. (2016) · Angewandte Chemie · doi:10.1002/ange.201608568 · Cited by 3

Role of Signaling Pathways Regulating Cell Cycle Progression in Cancer

Nabi, N., Nisa, M. U., Khan, M. S., & Gillani, S. Q. (2025) · Springer eBooks · doi:10.1007/978-981-96-2763-9_12 · Cited by 3

Integrating phase 2 into phase 3 based on an intermediate endpoint while accounting for a cure proportion—With an application to the design of a clinical trial in acute myeloid leukemia

Rufibach, K., Heinzmann, D., & Monnet, A. (2019) · Pharmaceutical Statistics · doi:10.1002/pst.1969 · Cited by 3

Global Analyses to Identify Direct Transcriptional Targets of p53

Galbraith, M. D., Andrysík, Z., Sullivan, K. D., & Espinosa, J. M. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1217-0_3 · Cited by 3

A signature for success

Espinosa, J. M., & Sullivan, K. D. (2015) · eLife · doi:10.7554/elife.08773 · Cited by 3

Effect of Nutlin-3a on stability of p53-MDM2 complex

Zhou, H., Geng, Y.-Z., & Yan, S. (2023) · Acta Physica Sinica · doi:10.7498/aps.72.20222441 · Cited by 3

Targeting the MDM2–p53 Protein–Protein Interaction

Hardcastle, I. R. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-396521-9.00013-9 · Cited by 3

Targeting of Apoptosis Signaling Pathways and Their Mediators for Cancer Therapy

Rishi, A. K., Zhang, X., & Wali, A. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0131-6_5 · Cited by 4

PTEN loss drives p53 LOH and immune evasion in a novel urothelial organoid model harboring p53 missense mutations

Hamada, A., Kita, Y., Sakatani, T., Nakamura, K. D., Takada, H., Ikeuchi, R., Koike, S., Masuda, N., Murakami, K., Sano, T., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03311-5 · Cited by 2

MDM2 inhibitor induces apoptosis in colon cancer cells through activation of the CHOP-DR5 pathway, independent of p53 phenotype

Lu, M., Ren, Y., Feng, S., Wang, S., Xia, W., Gu, B., Shen, Y., Yue, A., Li, N., Zhang, Y., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1508421 · Cited by 2

Triazole-stapled p53 mimetics as MDM2 inhibitors: structural and thermodynamic origin of enhanced binding affinity

Gaikwad, V., Venugopal, P. P., & Chakrabarti, R. (2026) · Physical Chemistry Chemical Physics · doi:10.1039/d5cp03813h · Cited by 3

Regulation of p53 Activity and Associated Checkpoint Controls

Post, S. M., Quintás‐Cardama, A., & Lozano, G. (2009) · Humana Press eBooks · doi:10.1007/978-1-60761-178-3_11 · Cited by 2

Uncovering dual oscillatory regimes in p53-mdm2 dynamics: A data-driven modeling approach with implications for cancer suppression

Menta, K., Bani-Yaghoub, M., & Youan, B.-B. C. (2025) · Biosystems · doi:10.1016/j.biosystems.2025.105540 · Cited by 2

MDM2-dependent inhibition of P53 is required for Epstein-Barr virus B cell growth transformation and infected cell survival

Forte, E., & Luftig, M. (2009) · Infectious Agents and Cancer · doi:10.1186/1750-9378-4-s2-p26 · Cited by 2

Targeting Proteasomal Degradation of Soluble, Misfolded Proteins

Seneci, P. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801944-3.00003-5 · Cited by 2

Molecular analysis confirms retinoblastoma diagnosis in a histologically undifferentiated retinal tumor in an adult

Soliman, S. E., Méndez-Martínez, S., Nicola, M. L. D., Kiehl, R., & Krema, H. (2020) · Ophthalmic Genetics · doi:10.1080/13816810.2020.1765398 · Cited by 2

Pharmacological activation of the p53 pathway by a new compound CYZ2017 exerts anti-tumor effects

Han, Y., Ren, Z., Wu, Y., Chen, Y., Cui, Z., Zhu, T., Ma, M., Du, Y., & Dong, S. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.09.122 · Cited by 2

Resembling the bottleneck effect in p53 core network including the dephosphorylation of ATM by Wip1: A computational study

Wang, D., Wang, Y., Lü, H., Wu, Z., & Liang, X. (2022) · Frontiers in Physics · doi:10.3389/fphy.2022.1017218 · Cited by 2

Single cell CRISPR base editor engineering and transcriptional characterization of cancer mutationsPreprint

Kim, H. S., Grimes, S. M., Sathe, A., Lau, B. T., & Ji, H. P. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.31.514258 · Cited by 2

Ferroptosis as a therapeutic vulnerability in MDM2 inhibition in dedifferentiated liposarcoma

Yen, C., Chen, P., Chen, S., Wu, W., Yen, C., Lin, Y., Wu, P., Chen, C.-M., Wang, J., Chao, T., et al. (2025) · Oncology Letters · doi:10.3892/ol.2025.15015 · Cited by 1

Synthesis and Biological Evaluation of a Novel Dual-Targeting Small Molecule Drug Conjugate Modulating the Crosstalk between α5β1 Integrin and MDM2 in Glioblastoma

Arrigoni, F., Ferrari, A., Prpić, H., Markevičiūtė, E., Muzi, A., Roscilli, G., Gazzola, S., & Piarulli, U. (2026) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5c00669 · Cited by 1

Exploring the binding dynamics of triazolyl-thio-oxazines for MDM2-p53 disruption: Design, synthesis, and p53 upregulation

Narasimhachar, B. C., Nagaraja, O., Ahn, K. S., Yang, M. H., Harish, K. K., Madegowda, M., Bender, A., Basappa, B., & Chandrashekara, P. G. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.151392 · Cited by 1

Context matters in PROTAC design: navigating the trade-off between degradation and developability

Zhang, B., Zhang, Y., Zhang, B., Hu, J., Ke, C., Wu, T., Wei, M., Xia, J., Wang, M., Zhao, Q., et al. (2026) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2026.2707656 · Cited by 1

Targeting p53 Tumor Suppressor for AML Therapy

Kojima, K., & Vassilev, L. T. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1393-0_7 · Cited by 1

Oncogenes and Tumor Suppressor Genes as a Biomarker in Breast Cancer

Üçtepe, E., Acar, M., Gündüz, E., & Gündüz, M. (2014) · Springer eBooks · doi:10.1007/978-81-322-0843-3_3 · Cited by 1

Molecular Pathogenesis of Urothelial Carcinoma and the Development of Novel Therapeutic Strategies

Thomas, C. Y., & Theodorescu, D. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-417-9_26 · Cited by 1

MOLECULAR GENETICS OF SOFT TISSUE TUMORS

Lasota, J. P. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511781049.006 · Cited by 1

Targeting the p53 tumor suppressor gene function in glioblastomas using small chemical molecules

Magrini, R., Bakker, A. C., Gaviraghi, G., & Terstappen, G. C. (2006) · Drug Development Research · doi:10.1002/ddr.20151 · Cited by 1

Phase I studies

Berry, S. M., Carlin, B., Lee, J., & Müller, P. (2010) · CRC Press eBooks · doi:10.1201/ebk1439825488-6

The facile and visualizable identification of broad-spectrum inhibitors of MDM2/p53 using co-expressed protein complexes

Yang, Y., Dong, Z., Hu, H., Peng, J., Sheng, Y., Yang, T., Yuan, S., Li, Z., Yang, J., Wells, T., et al. (2019) · The Analyst · doi:10.1039/c9an00350a · Cited by 1

Bone Tumors: Types and Treatments

Tomar, G. B., Dave, J. R., Chandekar, S. S., & Mhaske, S. T. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.86550 · Cited by 1

Resistance of human primary mesenchymal stem cells to cytotoxic effects of nutlin‐3 in vitro

Bajelan, B., Zaki‐Dizaji, M., Rahmani, B., Darzi, S., Darabi, S., & Rajaei, F. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29324 · Cited by 1

Induction of synergistic apoptosis by tetramethoxystilbene and nutlin-3a in human cervical cancer cells

An, H.-G., Shin, S., Lee, B., Kwon, Y., Kwon, T.-U., Kwon, Y., & Chun, Y. (2022) · Toxicological Research · doi:10.1007/s43188-022-00150-4 · Cited by 1

Predicting p53-dependent cell transitions from thermodynamic models

Gautam, P., Ciuta, I., Teif, V. B., & Sinha, S. K. (2024) · The Journal of Chemical Physics · doi:10.1063/5.0225166 · Cited by 1

Engineering ERα degraders with pleiotropic ubiquitin ligase ligands maximizes therapeutic efficacy by co-opting distinct effector ligases

Shemorry, A., den Besten, W., Mulvihill, M. M., Essenburg, C. J., Blaquière, N., Kleinheinz, T., Villemure, E., Peale, F., Deshmukh, G. S., Maddalo, D., et al. (2025) · Cell chemical biology · doi:10.1016/j.chembiol.2025.04.008 · Cited by 1

Abstract SY18-01: Targeting the p53-MDM2 interaction for cancer therapy

Vassilev, L. T. (2010) · Cancer Research · doi:10.1158/1538-7445.am10-sy18-01

Abstract 977: Elevated MDM2 protein contributes to activity of MDM2 antagonists by enabling p53 induction of antitumor microRNAs

Xia, M., Huang, B., Chu, W., & Vassilev, L. T. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-977

Small-Molecule Antagonists of p53-MDM2 Binding: Research Tools and Potential Therapeutics

Vassilev, L. T. (2004) · Cell Cycle · doi:10.4161/cc.3.4.801 · Cited by 271

Elevated MDM2 contributes to antitumor activity of p53-MDM2 binding inhibitors

Xia, M., Knezevic, D., Tovar, C., Heimbrook, D. C., & Vassilev, L. T. (2007) · Molecular Cancer Therapeutics

Abstract C128: Small-molecule antagonists of MDM2 and MDMX.

Thompson, T., Graves, B. J., Xia, M., Janson, C. A., Lukacs, C., Deo, D. D., Huang, K., Tovar, C., Lovey, A. J., Wanner, J., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-11-c128